Compugen Ltd.

NasdaqCM:CGEN Stock Report

Market Cap: US$208.6m

Compugen Future Growth

Future criteria checks 0/6

Compugen's earnings are forecast to decline at 43.4% per annum while its annual revenue is expected to grow at 0.8% per year. EPS is expected to decline by 40% per annum.

Key information

-43.4%

Earnings growth rate

-40.0%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate0.8%
Future return on equityn/a
Analyst coverage

Low

Last updated13 Jan 2025

Recent future growth updates

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28
Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Earnings and Revenue Growth Forecasts

NasdaqCM:CGEN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202747-17-28N/A3
12/31/202639-117N/A3
12/31/202534-11-10N/A3
12/31/202444-397N/A3
9/30/2024602N/AN/AN/A
6/30/202443-102222N/A
3/31/202436-17N/AN/AN/A
12/31/202333-19-36-36N/A
9/30/20238-32N/AN/AN/A
6/30/20238-33-32-32N/A
3/31/20238-33N/AN/AN/A
12/31/20228-34-35-34N/A
9/30/2022N/A-39N/AN/AN/A
6/30/20226-34-30-30N/A
3/31/20226-34N/AN/AN/A
12/31/20216-34-23-23N/A
9/30/20218-34N/AN/AN/A
6/30/20212-36-31-30N/A
3/31/20212-32N/AN/AN/A
12/31/20202-30-28-28N/A
9/30/2020N/A-28N/AN/AN/A
6/30/2020N/A-26-23-23N/A
3/31/2020N/A-26N/AN/AN/A
12/31/2019N/A-27-28-28N/A
9/30/2019N/A-30N/AN/AN/A
6/30/20198-27-22-22N/A
3/31/20198-31N/AN/AN/A
12/31/201818-23-13-13N/A
9/30/201818-23N/AN/AN/A
6/30/201810-29N/A-23N/A
3/31/201810-28N/AN/AN/A
12/31/2017N/A-37N/A-31N/A
9/30/20170-36N/AN/AN/A
6/30/20170-34N/A-27N/A
3/31/20171-32N/AN/AN/A
12/31/20161-32N/A-20N/A
9/30/20169-23N/AN/AN/A
6/30/20169-22N/A-20N/A
3/31/20169-23N/AN/AN/A
12/31/20159-20N/A-26N/A
9/30/20158-21N/AN/AN/A
6/30/20159-20N/A-17N/A
3/31/201511-15N/AN/AN/A
12/31/201412-11N/A-11N/A
9/30/20148-13N/AN/AN/A
6/30/20147-12N/A-7N/A
3/31/20146-13N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CGEN's earnings are forecast to decline over the next 3 years (-43.4% per year).

Earnings vs Market: CGEN's earnings are forecast to decline over the next 3 years (-43.4% per year).

High Growth Earnings: CGEN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: CGEN's revenue (0.8% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: CGEN's revenue (0.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CGEN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 10:49
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Compugen Ltd. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Varun KumarCantor Fitzgerald & Co.
Ling WangChardan Capital Markets, LLC
Vernon BernardinoFBR Capital Markets & Co.